Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Scott, R.J.
Right arrow Articles by McLaren, G.I.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Scott, R.J.
Right arrow Articles by McLaren, G.I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 1996; 89: 613-622
© 1996 Association of Physicians

Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice

R.J. Scott, W.R.C. Aitchison1, P.R. Barker2 and G.I. McLaren1

General Practice Units in Edinburgh UK 1 Renfrewshire UK 2 Great Missenden UK

Address correspondence to Dr RJ. Scott, The Surgery, 60 Leith Walk, Edinburgh EH6 5HB

Received 19 February 1996
  Abstract

We investigated the efficacy, safety and tolerability compared with placebo of a second dose of oral sumatriptan 100 mg in 1349 general practice patients who had already treated a moderate or severe migraine headache with 100 mg sumatriptan 4 h earlier. Headache was relieved by the first sumatriptan dose in about 70%of patients, but the second dose did not produce significantly more relief than placebo, either in non-responders or in the group as a whole, nor did it reduce other symptoms (photophobia, nausea, vomiting, etc.) at 8 h, or influence the incidence of headache recurrence. The drug was well-tolerated, and a further single dose was effective in treating recurrence after initial relief. A single 100 mg dose of sumatriptan is an effective acute treatment for migraine. A second dose should be reserved for treating headache recurrence.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CephalalgiaHome page
C. Dahlo, A. Hauge, and J Olesen
Efficacy and Safety of Tonabersat, a Gap-Junction Modulator, in the Acute Treatment of Migraine: A Double-Blind, Parallel-group, Randomized Study
Cephalalgia, November 1, 2009; 29(2_suppl): 7 - 16.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.